Telo Genomics Highlights New MRD Methodology at The 2025 International Myeloma Society MeetingSeptember 19, 2025 8:30 AM EDT | Source: Telo Genomics Corp.Toronto, Ontario--(Newsfile Corp. - September 19, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of telomeres, today announced that the company has presented a poster abstract on minimal residual disease (" ...